AngioDynamics, Inc.
ANGOHealthcareNASDAQMedical Instruments & Supplies · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, AngioDynamics, Inc. focuses on Medical Instruments & Supplies services and products. AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells products for the treatment of cardiovascular disease and cancer diagnoses in the United States and internationally. Valued at $520.0M, ANGO is a small-cap name in its sector. The company operates through Med Tech and Med Device segments.
Market Cap
$520.0M
Beta
0.30
P/E (TTM)
—
P/E (Fwd)
-109.11
EPS (TTM)
$-0.78
EPS (Fwd)
$-0.11
ROE
-19.2%
ROA
-5.1%
Cash
$34.0M
Total Debt
$10.7M
Free CF
$21.3M
52W Change
0.7%
Annual Financials
Cash vs Debt
Where ANGO stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ANGO finished 12.05% below its 150-day moving average ($12.95) and 8.29% below its 200-day moving average ($12.42). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ANGO overbought or oversold?
At the October 20, 2026 close, ANGO's RSI(14) was 21.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
AngioDynamics, Inc. holds $34.0M in cash against $10.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company generates $21.3M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -19.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been relatively flat, moving from $338.8M (2023) to $320.2M (2026).
ANGO's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, ANGO has financial flexibility that may help navigate uncertain periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence AngioDynamics, Inc.'s trajectory.